{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:26Z","timestamp":1792788746179,"version":"4.5.0"},"reference-count":45,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer,","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CMC AFFINITY"},{"name":"McCann Health Medical Communications"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.2217\/fon-2021-1250","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T05:41:03Z","timestamp":1639719663000},"page":"781-791","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Encorafenib Plus Binimetinib in Patients with\n                    <i>BRAF<\/i>\n                    <sup>V600<\/sup>\n                    -Mutant Non-Small Cell Lung Cancer: Phase II PHAROS Study Design"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5357-4313","authenticated-orcid":false,"given":"Gregory J","family":"Riely","sequence":"first","affiliation":[{"name":"Department of Medicine,Memorial Sloan Kettering Cancer Center,\rNew York,\rNY\r10065,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9654","authenticated-orcid":false,"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology,Samsung Medical Center,\rSeoul,\r06351,\rRepublic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-0098","authenticated-orcid":false,"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[{"name":"Oncology Department, Vall d\u2019Hebron Institute of Oncology,Vall d\u2019Hebron University Hospital,\rBarcelona,\r08035,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-3106","authenticated-orcid":false,"given":"Suresh S","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology,Emory University School of Medicine,\rAtlanta,\rGA\r30322,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-6995","authenticated-orcid":false,"given":"Egbert F","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology,Netherlands Cancer Institute,\rAmsterdam,\r1066,\rCX,\rThe Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-6639","authenticated-orcid":false,"given":"Anne S","family":"Tsao","sequence":"additional","affiliation":[{"name":"Department of Thoracic\/Head and Neck Medical Oncology,MD Anderson Cancer Center,\rTX\r77030,\rHouston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Alcasid","sequence":"additional","affiliation":[{"name":"Clinical Development and Operations,Pfizer Inc.,\rCollegeville,\rPA\r19426,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Usari","sequence":"additional","affiliation":[{"name":"Biostatistics,Pfizer,\rMilan,\r20152,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-8875","authenticated-orcid":false,"given":"Paul S","family":"Wissel","sequence":"additional","affiliation":[{"name":"Clinical Development and Operations,Pfizer Inc.,\rCollegeville,\rPA\r19426,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2276-7865","authenticated-orcid":false,"given":"Keith D","family":"Wilner","sequence":"additional","affiliation":[{"name":"Clinical Development and Operations,Pfizer Inc.,\rSan Diego,\rCA\r92121,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,Dana-Farber Cancer Institute,\rBoston,\rMA\r02215,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040804"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916623"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00004-0"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0657"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320956111"},{"key":"e_1_3_7_9_1","first-page":"212566","article-title":"Agents to treat BRAF-mutant lung cancer","volume":"8","author":"Alvarez JGB","year":"2019","unstructured":"Alvarez JGB , OttersonGA. Agents to treat BRAF-mutant lung cancer. Drugs Context8, 212566 (2019).","journal-title":"Drugs Context"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103008"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.10.22"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01068-8"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0458"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000344"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210093"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00489"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000491"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.07.016"},{"key":"e_1_3_7_20_1","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)","author":"National Comprehensive Cancer Network\u00ae","year":"2021","unstructured":"National Comprehensive Cancer Network\u00ae . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Melanoma: Cutaneous Version 2.2021 (2021). www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf","journal-title":"Melanoma: Cutaneous Version 2.2021"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30146-2"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30679-4"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00077-2"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.011"},{"key":"e_1_3_7_30_1","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)","author":"National Comprehensive Cancer Network\u00ae","year":"2021","unstructured":"National Comprehensive Cancer Network\u00ae . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer Version 5.2021 (2021). www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf","journal-title":"Non-Small Cell Lung Cancer Version 5.2021"},{"key":"e_1_3_7_31_1","volume-title":"Presented at: AACR 103rd Annual Meeting.","author":"Stuart D","year":"2012","unstructured":"Stuart D , LiN, PoonDJet al. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor. Presented at: AACR 103rd Annual Meeting.Chicago, IL, USA31 March - 4 April 2012."},{"key":"e_1_3_7_32_1","volume-title":"Presented at: AACR 101st Annual Meeting.","author":"Lee PA","year":"2010","unstructured":"Lee PA , WallaceE, MarlowAet al. Preclinical development of ARRY-162, a potent and selective MEK 1\/2 inhibitor. Presented at: AACR 101st Annual Meeting.Washington, DC, USA17-21 April 2010."},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000426"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2923"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30497-2"},{"issue":"10","key":"e_1_3_7_36_1","first-page":"745","article-title":"In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma","volume":"15","author":"Flaherty K","year":"2017","unstructured":"Flaherty K . In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma. Clin. Adv. Hematol. Oncol.15(10), 745\u2013747 (2017).","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"15","key":"e_1_3_7_37_1","article-title":"Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAFV600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial","volume":"39","author":"Ascierto PA","year":"2021","unstructured":"Ascierto PA , RobertC, NathanPDet al. Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAFV600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial. J. Clin. Oncol.39(Suppl. 15), Abstract 9560 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"e_1_3_7_38_1","article-title":"Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): primary results of COMBI-APlus","volume":"39","author":"Atkinson V","year":"2021","unstructured":"Atkinson V , RobertC, GrobJ-Jet al. Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): primary results of COMBI-APlus. J. Clin. Oncol.39(Suppl. 15), Abstract 9525 (2021).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_7_39_1","unstructured":"Pfizer Inc . BRAFTOVI\u00ae (encorafenib): Prescribing Information (2021). http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=12990#S2.1"},{"key":"e_1_3_7_40_1","unstructured":"Pfizer Inc . MEKTOVI\u00ae (binimetinib): Prescribing Information (2021). http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=12988"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0170"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406766"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.6352"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-1250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:43:21Z","timestamp":1719110601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-1250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.2217\/fon-2021-1250"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-1250","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}